Q4 2025 · 13F-HR
Flagship Pioneering, LLCholdings as filed
Filed 2026-02-17 · accession 0001193125-26-054539
$324.0M
Reported value
4
Positions
2025-12-31
Period end
The Brief · Flagship Pioneering, LLC · Q4 2025
AI · grounded in 13F
Flagship Pioneering, LLC reported no changes to its 13F holdings for 2025-12-31 relative to 2025-09-30.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 60770K107 | MRNA | Moderna Inc | $136.6M | 42.2% | 4,632,149 | Common | SHARED |
| 799566104 | SANA | Sana Biotechnology Inc | $101.8M | 31.4% | 25,001,856 | Common | SHARED |
| 344174107 | FHTX | Foghorn Therapeutics Inc | $68.4M | 21.1% | 12,674,120 | Common | SHARED |
| 81750R201 | MCRB | Seres Therapeutics Inc | $17.2M | 5.32% | 1,155,850 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.